

Ref: GLL/BSE/2025-26/Nov -

Date: November 14, 2025

To  
The General Manager,  
Corporate Relations Department,  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, **Mumbai - 400001.**  
Maharashtra State, India.  
**Script Code: 531739**

To  
The Listing Manager,  
**The Ahmedabad Stock Exchange Limited**  
A-2, Kamdhenu Complex, Opp. Sahajanand  
College, 120 Feet Ring Road, Panjara Pol,  
Ambawadi, **Ahmedabad - 380015.**  
Gujarat State, India.  
**Script Code:**

To  
**The Calcutta Stock Exchange Limited,**  
#7, Lyons Range, Murgighata,  
Dalhousie, **Kolkata - 700001,**  
West Bengal State, India.  
**Scrip Code: 26178**

Dear Sir/Madam,

**Sub: Outcome of the Board Meeting of Gennex Laboratories Limited - Scrip Code: 531739/GENNEX**

**Ref: Regulation 29, 33 & 47 of the SEBI (LODR) 'Regulations, 2015.**

In just concluded Meeting of Board of Directors, the Board Approved and considered the following items:

1. Unaudited (Standalone and Consolidated) Financial Statements for the Quarter and Half year ended September 30, 2025 (annexed herewith);
2. Limited review reports from the Statutory Auditor on Unaudited (Standalone and Consolidated) Financial Statements for the Quarter and Half year ended September 30, 2025 (annexed here with);
3. Other Business items.

We hereby submit that the Board Meeting had commenced at 04:00 PM and concluded at 5:00 PM.

This intimation is also uploaded on the Company website: [www.gennexlab.com](http://www.gennexlab.com).

We request you to take the above information on record and acknowledge the receipt of the same.

Thanking you,

Yours faithfully,

**For Gennex Laboratories Limited**

Dinesh Kumar  
Kejriwal  
**Dinesh Kumar Kejriwal**  
Company Secretary & Compliance Officer  
Membership #A19293

Digitally signed by Dinesh  
Kumar Kejriwal  
Date: 2025.11.14 17:08:06  
+05'30'

## Gennex Laboratories Limited

Office: 'Akash Ganga' 4<sup>th</sup> Floor, Plot NO.144, Srinagar colony, Hyderabad-500073, T.S. India | Phone: +91-40-67334400 (30 Lines), Fax: +91-40-67334433  
Factory: Sy.No.133, IDA Bollaram, Jinnaram Mandal, Sangareddy Dist - 502325, Telangana, India | Tel: +91-08458 279406, Telefax: +91-08454 279516

[Info@gennexlab.com](http://Info@gennexlab.com), [www.gennexlab.com](http://www.gennexlab.com) ■ CIN :L24230TG1990PLC011168

**GENNEX LABORATORIES LIMITED**

CIN: L24230TG1990PLC011168

REGD. OFF: Survey #133, IDA Bollaram, Jinnaram mandal, Medak District - 502 325, Telanaga State, India.

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER/HALF YEAR ENDED 30TH SEPTEMBER, 2025

Tel. No.+91-40-67334400-30, Fax: +91-40-67334433, Email: info@gennexlab.com website: www.gennexlab.com

**(All amounts in Rs.lakhs except EPES and Ratios)**

Statement of Standalone Unaudited Financial Results for the Quarter and Six months ended September 30, 2025							(Rs. in lakhs)
Sl. No.	Particulars	Quarter Ended			Half Year Ended		Year ended
		30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31.03.2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	<b>Income from Operations</b>						
	(a) Revenue from Operations	2,932.63	2,564.00	2,468.59	5,496.63	4,601.99	9,457.79
	(b) Other operating Income	204.18	226.44	182.42	430.62	428.35	922.13
	<b>Total Income from operations (net)</b>	<b>3,136.81</b>	<b>2,790.44</b>	<b>2,651.01</b>	<b>5,927.25</b>	<b>5,030.34</b>	<b>10,379.92</b>
2	<b>Expenses</b>						
	(a) Cost of material consumed	2,656.90	1,826.97	1,388.84	4,483.87	2,507.71	6,718.15
	(b) Purchases of stock-in-trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-694.07	-98.80	216.07	-792.87	429.22	642.50
	(d) Employee benefit expense	187.64	188.03	149.20	375.67	339.63	76.95
	(e) Finance Cost	55.45	59.15	46.97	114.60	64.15	158.45
	(f) Depreciation and amortisation expense	20.70	19.87	5.21	40.57	34.70	1,132.85
	(g) Other expenses	386.88	310.26	343.87	697.14	662.48	8,658.76
	<b>Total expenses</b>	<b>2,613.50</b>	<b>2,305.49</b>	<b>2,150.15</b>	<b>4,918.98</b>	<b>4,037.89</b>	<b>1,721.15</b>
3	<b>Profit(+)/Loss(-) from operations before exceptional items and tax (1-2)</b>	523.32	484.95	500.85	1,008.27	992.45	15.00
4	<b>Exceptional items</b>	-	-	-	-	-	-
5	<b>Profit(+)/Loss(-) before tax (3+4)</b>	523.32	484.95	500.85	1,008.27	992.45	1,706.15
6	<b>Tax Expenses for earlier years</b>						
7	<b>Current Tax</b>	-70.00	-70.00	-85.00	-140.00	-160.00	-297.00
8	<b>Deferred tax</b>						
9	<b>Total Tax expense</b>	-70.00	-70.00	-85.00	-140.00	-160.00	-302.47
10	<b>Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement</b>	-	-	-	-	-	-
11	<b>Net Profit for the period from continuing operation (5-9)</b>	<b>453.32</b>	<b>414.95</b>	<b>415.85</b>	<b>868.27</b>	<b>832.45</b>	<b>1,403.68</b>
12	<b>Profit(+)/Loss(-) from discontinued operations before tax</b>						
13	<b>Tax expense of discontinued operations</b>	-	-	-	-	-	-
14	<b>Net Profit(loss) for the period from discontinued operations</b>	-	-	-	-	-	-
15	<b>Share of Profit(loss) of associates and Joint Ventures accounted for using equity method</b>	-	-	-	-	-	-
16	<b>Total profit(loss) for period</b>	453.32	414.95	415.85	868.27	832.45	1,403.68
17	<b>Other comprehensive Income net of taxes</b>	-	-	-	-	-	-
18	<b>Net profit(loss) for period</b>	<b>453.32</b>	<b>414.95</b>	<b>415.85</b>	<b>868.27</b>	<b>832.45</b>	<b>1,403.68</b>
19	<b>Paid-up Equity Share Capital</b>						
	(Face value Rs. 1 each Equity Share)	2,429.48	2,314.48	2,274.47	2,429.48	2,274.47	2,274.48
	<b>Other Equity</b>						
20	<b>Earning Per Equity Share (EPS) (Face value of Rs 1 per Share) ( of Rs. 1 each ) (not annualised) :</b>						
	(a) Basic	0.187	0.179	0.183	0.357	0.366	0.617
	(b) Diluted	0.187	0.171	0.183	0.357	0.366	0.607

**Standalone Notes:**

- The statement of Standalone unaudited financial results of the Company for the Quarter and Half-Year ended September 30, 2025, has been reviewed by the Audit Committee and approved by the Board of Directors on November 14, 2025. These have been reviewed by the R Pugalia & Co., the Statutory Auditor of the Company, who have issued an unmodified qualified review report.
- The standalone unaudited financial results of Gennex Laboratories Limited ('the Company') have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 'Interim Financial Reporting' Indian Accounting Standards (Ind AS) notified under section 133 of the Companies Act 2013 ('the Act'), read with the Companies (Indian Accounting Standard) Rule, 2015, as amended from time to time and other accounting principles generally accepted in India.
- The Company operating segment is "Bulk Drugs" Manufacturing as its deals mainly with Guaifenesin, Methocarbamol, it also does business outside India. The Company operates in single segment and therefore the Segment Reporting as per AS-17 is not applicable for the Company.
- Previous period's figures have been rearranged / regrouped wherever necessary
- The quarterly unaudited standalone Financial results for the Quarter and Half Year ended September 30, 2025 are available on the Company's Website i.e., www.gennexlab.com and also available on BSE website i.e., www.bseindia.com.

**For Gennex Laboratories Limited**

ARIHANT BAID Digitally signed by ARIHANT BAID

**Arihant Baid**

Managing Director

Date: 14.11.2025

Place: Hyderabad



## GENNEX LABORATORIES LIMITED

### Statement of Assets and Liabilities - Standalone

(Rs. in lakhs)

Particulars	As at September 30,2025 Unaudited	As at March 31,2025 Audited
<b>B) ASSETS</b>		
<b>1 Non-Current Assets</b>		
a) Tangible Assets	2,004.49	1,965.21
b) Intangible Assets	359.38	262.41
c) Non-Current Investments	826.42	826.42
d) Long-term loans and advances	81.86	81.85
<b>E</b>		
Sub-total Non-current assets	<b>3,272.14</b>	<b>3,135.89</b>
<b>2 Current Assets</b>		
a) Current Investments		-
b) Inventories	3,789.39	2,458.56
c) Trade receivable	2,915.55	1,189.07
d) Cash and Cash equivalents	4,801.80	5,556.23
e) Short-term loans and advances	11,340.55	9,059.16
f) Other current assets	493.27	439.38
<b>Sub-total - Current assets</b>	<b>23,340.56</b>	<b>18,702.39</b>
<b>TOTAL - ASSETS</b>	<b>26,612.70</b>	<b>21,838.28</b>
<b>A) EQUITY AND LIABILITIES</b>		
<b>1 Shareholders' Funds:</b>		
a) Share Capital	2,429.48	2,274.48
b) Equity Warrants	-	571.95
c) Reserves and Surplus	18,632.71	15,633.20
Sub-total Shareholders' Fund	<b>21,062.19</b>	<b>18,479.63</b>
<b>2 Non - Current Liabilities</b>		
a) Long-term borrowings	419.68	447.49
Sub-total Non-current liabilities	<b>419.68</b>	<b>447.49</b>
<b>3 Current Liabilities</b>		
a) Short-term borrowings	2,221.73	124.26
b) Trade payables	1,319.79	1,084.32
c) Other current liabilities	714.63	927.70
d) Short-term provisions	874.67	774.88
<b>Sub-total Current liabilities</b>	<b>5,130.82</b>	<b>2,911.16</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>26,612.70</b>	<b>21,838.28</b>

**For Gennex Laboratories Limited**

ARIHANT BAID

Digitally signed by ARIHANT  
BAID  
Date: 2025.11.14 17:05:07  
+05'30'

**Arihant Baid**

Managing Director

Date: 14.11.2025

Place: Hyderabad

**GENNEX LABORATORIES LIMITED**  
**Standalone Cash Flow Statement**



	30-09-2025 (Rs. In Lacs)	31-03-2025 (Rs. In Lacs)
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>		
<b>Net Profit before Tax</b>	<b>868.26</b>	<b>1706.15</b>
<b>Adjustment for :</b>		
Depreciation and amoratisation expense	40.57	76.95
Finance Cost	114.59	158.46
Interest Income	-381.26	-839.07
(Gain)/loss on sale of asset		0
<b>Operating Profit before working capital changes</b>	<b>642.17</b>	<b>1102.49</b>
<b>Adjustment for :</b>		
Trade payables and other liability	235.48	-350.81
Trade receivables	-1726.49	167.72
Inventories	-1330.83	-851.31
Financial and other Assets	-2335.29	-659.48
Other Current Liabilities	-113.28	67.55
<b>Cash generated from operations</b>	<b>-4628.23</b>	<b>-658.94</b>
<b>Adjustments for :</b>		
Income Taxes paid		-297.00
<b>Net Cash from operating activities</b>	<b>-4628.23</b>	<b>-955.94</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>		
Purchase of property,plant and equipment	-176.81	-595.84
Sale of property,plant and equipment	0.00	19.97
Purchase of Equity Shares	0.00	0.00
Interest Income	381.26	839.07
<b>Net Cash used in Investing activities</b>	<b>204.45</b>	<b>263.20</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>		
Proceeds from Issue of Capital	1714.30	0.00
Changes in Long Term Borrowings	-27.82	271.69
Changes in Short Term Borrowings (Net)	2097.47	39.58
Interest Paid	-114.59	-158.45
<b>Net Cash from Financing activities</b>	<b>3669.36</b>	<b>152.82</b>
<b>Net Increase / (Decrease) in Cash and Cash equivalent ( A+B+C )</b>	<b>-754.42</b>	<b>-539.92</b>
<b>Cash and Cash Equivalents as at the beginning of the year</b>	<b>5556.23</b>	<b>6096.19</b>
<b>Cash and Cash Equivalents as at the end of the period</b>	<b>4801.81</b>	<b>5556.23</b>

Notes:

1. The above Cash Flow Statement has been prepared under the " Indirect Method" set out in Indian Accounting Standard (Ind- AS)- 7 on Statement of Cash Flow.
2. Figures in bracket indicate cash outflow.
3. Previous year comparatives have been reclassified to confirm with current year's presentation, wherever applicable.



**Limited Review report on Unaudited Standalone financial results for quarter and half year ended 30<sup>th</sup> September, 2025 of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015.**

To  
The Board of Directors,  
**M/s. Gennex Laboratories Limited,**  
**Hyderabad.**

We have reviewed the accompanying Statement of Unaudited Standalone financial results of **Gennex Laboratories Limited** for the Quarter and half year ended September 30, 2025 and for the period from April 01, 2025 to September 30, 2025 ("the statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

This statement is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliances with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data, thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated in paragraph 3 above nothing has come to our attention, except as stated below, that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including

the manner in which it is to be disclosed, or that it contains any material misstatement.

**For R PUGALIA & COMPANY**  
**Chartered Accountants**  
**Firm Registration No.318188E**

*R. Pugalia*

**RAJEEV KUMAR PUGALIA**  
**Membership No.053972**  
**Place: Kolkata**  
**Date: 14<sup>th</sup> November 2025**  
**UDIN : 25053972BMMKHZ8237**



**GENNEX LABORATORIES LIMITED**

CIN: L24230TG1990PLC011168

REGD. OFF: Survey #133, IDA Bollaram, Jinnaram mandal, Medak District - 502 325, Telanaga State, India.

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER/HALF YEAR ENDED 30TH SEPTEMBER, 2025

Tel. No.+91-40-67334400-30, Fax: +91-40-67334433, Email: info@gennexlab.com website: www.gennexlab.com

**(All amounts in Rs.lakhs except EPES and Ratios)**

Statement of Consolidated Unaudited Financial Results for the Quarter and Six months ended September 30, 2025							(Rs. in lakhs)
Sl. No.	Particulars	Quarter Ended			Half Year Ended		Year ended
		30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31.03.2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>1</b>	<b>Income from Operations</b>						
	(a) Revenue from Operations	3,724.21	3,417.75	3,154.89	7,141.96	5,987.07	13,790.30
	(b) Other operating Income	205.99	227.74	183.13	433.73	429.63	1,043.01
	<b>Total Income from operations (net)</b>	<b>3,930.20</b>	<b>3,645.49</b>	<b>3,338.02</b>	<b>7,575.69</b>	<b>6,416.70</b>	<b>14,833.31</b>
<b>2</b>	<b>Expenses</b>						
	(a) Cost of material consumed	3,055.68	2,381.96	2,088.93	5,437.64	3,891.13	10,058.95
	(b) Purchases of stock-in-trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-514.61	-162.26	-157.80	-676.87	-180.08	-350.58
	(d) Employee benefit expense	183.79	269.02	191.71	452.81	420.93	834.69
	(e) Finance Cost	102.91	97.90	111.41	200.81	156.70	199.08
	(f) Depreciation and amortisation expense	46.50	50.40	21.86	96.90	95.03	360.77
	(g) Other expenses	449.78	421.82	469.79	871.60	870.01	1,575.44
	<b>Total expenses</b>	<b>3,324.05</b>	<b>3,058.84</b>	<b>2,725.90</b>	<b>6,382.89</b>	<b>5,253.72</b>	<b>12,678.35</b>
<b>3</b>	<b>Profit(+)/Loss(-) from operations before exceptional items and tax (1-2)</b>	<b>606.15</b>	<b>586.64</b>	<b>612.12</b>	<b>1,192.80</b>	<b>1,162.98</b>	<b>2,154.96</b>
<b>4</b>	<b>Exceptional items</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-15.00</b>
<b>5</b>	<b>Profit(+)/Loss(-) before tax (3+4)</b>	<b>606.15</b>	<b>586.64</b>	<b>612.12</b>	<b>1,192.80</b>	<b>1,162.98</b>	<b>2,139.96</b>
<b>6</b>	<b>Tax Expenses for earlier years</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>7</b>	<b>Current Tax</b>	<b>-55.00</b>	<b>-85.00</b>	<b>-75.00</b>	<b>-140.00</b>	<b>-160.00</b>	<b>-322.00</b>
<b>8</b>	<b>Deferred tax</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-5.47</b>
<b>9</b>	<b>Total Tax expense</b>	<b>-55.00</b>	<b>-85.00</b>	<b>-75.00</b>	<b>-140.00</b>	<b>-160.00</b>	<b>-327.47</b>
<b>10</b>	<b>Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
	<b>Net Profit for the period from continuing operation (5-9)</b>	<b>551.15</b>	<b>501.64</b>	<b>537.12</b>	<b>1,052.80</b>	<b>1,002.98</b>	<b>1,812.49</b>
<b>12</b>	<b>Total profit(loss) for period</b>	<b>551.15</b>	<b>501.64</b>	<b>537.12</b>	<b>1,052.80</b>	<b>1,002.98</b>	<b>1,812.49</b>
<b>13</b>	<b>Other comprehensive Income net of taxes</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>14</b>	<b>Net profit(loss) for period</b>	<b>551.15</b>	<b>501.64</b>	<b>537.12</b>	<b>1,052.80</b>	<b>1,002.98</b>	<b>1,812.49</b>
<b>15</b>	<b>Profit Attributable to :</b>						
	Owners of the parent	<b>503.23</b>	<b>459.16</b>	<b>482.60</b>	<b>962.38</b>	<b>919.43</b>	<b>1,612.30</b>
	Non Controlling Interest	<b>47.92</b>	<b>42.48</b>	<b>54.52</b>	<b>90.42</b>	<b>83.55</b>	<b>200.19</b>
<b>15</b>	<b>Paid-up Equity Share Capital (Face value Rs. 1 each Equity Share)</b>	<b>2,429.48</b>	<b>2,314.48</b>	<b>2,274.47</b>	<b>2,429.48</b>	<b>2,274.47</b>	<b>2,274.47</b>
<b>16</b>	<b>Other Equity</b>						
	<b>Earning Per Equity Share (EPS) (Face value of Rs 1 per Share) ( of Rs. 1 each ) (not annualised) :</b>						
	(a) Basic	0.207	0.217	0.212	0.396	0.404	0.793
	(b) Diluted	0.207	0.206	0.212	0.396	0.400	0.784

**Consolidated Notes:**

- The statement of Consolidated unaudited financial results of the Company for the Quarter and Half-Year ended September 30, 2025, has been reviewed by the Audit Committee and approved by the Board of Directors on November 14, 2025. These have been reviewed by the R Pugalia & Co., the Statutory Auditor of the Company, who have issued an unmodified qualified review report.
- The Consolidated unaudited financial results of Gennex Laboratories Limited ('the Company') have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 'Interim Financial Reporting' Indian Accounting Standards (Ind AS) notified under section 133 of the Companies Act 2013 ('the Act'), read with the Companies (Indian Accounting Standard) Rule, 2015, as amended from time to time and other accounting principles generally accepted in India.
- The Company operating segment is "Bulk Drugs" Manufacturing as its deals mainly with Guaifenesin, Methocarbamol, it also does business outside India. The Company operates in single segment and therefore the Segment Reporting as per AS-17 is not applicable for the Company.
- Previous period's figures have been rearranged / regrouped wherever necessary
- The quarterly unaudited Consolidated Financial results for the Quarter and Half Year ended September 30, 2025 are available on the Company's Website i.e., www.gennexlab.com and also available on BSE website i.e., www.bseindia.com.

**For Gennex Laboratories Limited**ARIHANT BAID  
Digitally signed by ARIHANT BAID  
Date: 2025.11.14 17:04:48 +05'30'**Arihant Baid**  
Managing DirectorDate: 14.11.2025  
Place: Hyderabad



## GENNEX LABORATORIES LIMITED

### Statement of Assets and Liabilities - Consolidated

(Rs. in lakhs)

Particulars	As at September 30,2025 Unaudited	As at March 31,2025 Audited
<b>B) ASSETS</b>		
<b>1 Non-Current Assets</b>		
a) Tangible Assets	5,687.66	5,660.76
b) Intangible Assets	1,945.70	1,724.25
c) Non-Current Investments	-	-
d) Long-term loans and advances	105.62	105.61
<b>E</b>		
Sub-total Non-current assets	<b>7,738.98</b>	<b>7,490.62</b>
<b>2 Current Assets</b>		
a) Current Investments		-
b) Inventories	5,095.88	3,593.99
c) Trade receivable	4,375.60	1,416.12
d) Cash and Cash equivalents	4,802.39	5,556.90
e) Short-term loans and advances	13,145.98	7,076.98
f) Other current assets	545.76	468.94
<b>Sub-total - Current assets</b>	<b>27,965.60</b>	<b>18,112.91</b>
<b>TOTAL - ASSETS</b>	<b>35,704.58</b>	<b>25,603.53</b>
<b>A) EQUITY AND LIABILITIES</b>		
<b>1 Shareholders' Funds:</b>		
a) Share Capital	2,429.48	2,274.48
b) Equity Warrants	-	571.95
c) Reserves and Surplus	18,915.66	15,822.25
Non Controlling Interest	880.68	790.04
Sub-total Shareholders' Fund	<b>22,225.81</b>	<b>19,458.72</b>
<b>2 Non - Current Liabilities</b>		
a) Long-term borrowings	5,857.38	1,689.30
Sub-total Non-current liabilities	<b>5,857.38</b>	<b>1,689.30</b>
<b>3 Current Liabilities</b>		
a) Short-term borrowings	2,986.99	1,021.86
b) Trade payables	1,653.65	1,315.93
c) Other current liabilities	2,045.06	1,281.83
d) Short-term provisions	935.68	835.89
<b>Sub-total Current liabilities</b>	<b>7,621.38</b>	<b>4,455.51</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>35,704.58</b>	<b>25,603.53</b>

Date: 14.11.2025  
Place: Hyderabad

**For Gennex Laboratories Limited**

ARIHANT  
BAID

Digitally signed by  
ARIHANT BAID  
Date: 2025.11.14 17:05:24  
+05'30'

**Arihant Baid**  
Managing Director



**GENNEX LABORATORIES LIMITED**  
**Consolidated Cash Flow Statement**



	30-09-2025 (Rs. In Lacs)	31-03-2025 (Rs. In Lacs)
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>		
<b>Net Profit before Tax</b>	<b>1052.80</b>	<b>2139.96</b>
<b>Adjustment for :</b>		
Depreciation and amoratisation expense	<b>96.90</b>	<b>199.08</b>
Finance Cost	<b>200.82</b>	<b>360.77</b>
Interest Income	<b>-381.26</b>	<b>-957.08</b>
(Gain)/loss on sale of asset		
<b>Operating Profit before working capital changes</b>	<b>969.26</b>	<b>1741.73</b>
<b>Adjustment for :</b>		
Trade payables and other liability	<b>337.72</b>	<b>-202.09</b>
Trade receivables	<b>-2959.48</b>	<b>365.00</b>
Inventories	<b>-1501.90</b>	<b>-1076.50</b>
Financial and other Assets	<b>-6124.73</b>	<b>1763.89</b>
Other Current Liabilities	<b>863.03</b>	<b>177.07</b>
<b>Cash generated from operations</b>	<b>-8416.11</b>	<b>-757.68</b>
<b>Adjustments for :</b>		
Income Taxes paid		<b>-322.00</b>
<b>Net Cash from operating activities</b>	<b>-8416.11</b>	<b>-1079.68</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>		
Purchase of property,plant and equipment	<b>-366.34</b>	<b>-894.68</b>
Sale of property,plant and equipment	<b>0.00</b>	<b>19.97</b>
Purchase of Equity Shares	<b>0.00</b>	<b>0.00</b>
Increase in Security Deposit	<b>0.00</b>	<b>957.08</b>
Interest Income	<b>381.26</b>	<b>0.00</b>
<b>Net Cash used in Investing activities</b>	<b>14.92</b>	<b>82.37</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>		
Proceeds from Issue of Capital	<b>1714.30</b>	<b>0.00</b>
Changes in Long Term Borrowings	<b>4168.08</b>	<b>367.66</b>
Changes in Short Term Borrowings (Net)	<b>1965.13</b>	<b>449.81</b>
Interest Paid	<b>-200.82</b>	<b>-360.77</b>
<b>Net Cash from Financing activities</b>	<b>7646.69</b>	<b>456.70</b>
<b>Net Increase / (Decrease) in Cash and Cash equivalent ( A+B+C )</b>	<b>-754.50</b>	<b>-540.60</b>
<b>Cash and Cash Equivalents as at the beginning of the year</b>	<b>5556.90</b>	<b>6097.50</b>
<b>Cash and Cash Equivalents as at the end of the period</b>	<b>4802.40</b>	<b>5556.90</b>

Notes:

1. The above Cash Flow Statement has been prepared under the " Indirect Method" set out in Indian Accounting Standard (Ind- AS)- 7 on Statement of Cash Flow.
2. Figures in bracket indicate cash outflow.
3. Previous year comparatives have been reclassified to confirm with current year's presentation, wherever applicable.

**Limited Review report on Unaudited Consolidated financial results for quarter and half year ended 30<sup>th</sup> September, 2025 of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015.**

To  
The Board of Directors,  
**M/s. Gennex Laboratories Limited,**  
**Hyderabad.**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **M/s. Gennex Laboratories Limited** ("the Company") and its share of the net profit/(loss) after tax and total comprehensive income / loss of its Subsidiary for the quarter and half year ended September 30, 2025, and for the period from April 01, 2025 to September 30, 2025 ("the Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures corresponding quarter and half year ended September 30, 2025 as reported in these financial results have been approved by the Company's Board of Directors, but have not been subjected to review.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act, and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of Deccan Remedies Limited. (Subsidiary Company)

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement. prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The accompanying unaudited consolidated financial results includes unaudited interim financial results and other unaudited financial information in respect of 1 Subsidiary, which have been reviewed by other auditors, whose interim financial results excluding consolidation eliminations reflect total revenues of Rs.793.39 Lakhs, total net Profit after tax of Rs.97.83 Lakhs for the quarter and half year ended September 30, 2025 as considered in the unaudited consolidated financial results. These unaudited financial results and other unaudited financial information have been approved and furnished to us by the management. Our conclusion, in so far as it relates to the affairs of this Subsidiary, is based solely on such unaudited financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

**For R PUGALIA & COMPANY**  
**Chartered Accountants**  
**Firm Registration No.318188E**

*R. Pugalia*

**RAJEEV KUMAR PUGALIA**  
**Membership No.053972**  
**Place: Kolkata**  
**Date: 14<sup>th</sup> November 2025**  
**UDIN : 25053972BMMKHY5699**



# Gennex Laboratories Limited

## Segment Reporting (Country Wise)

The following table shows the distribution of the Company's revenue based on the location of the customers:

(Rs. In Lakhs)

Particulars	Quarter Ended			Half Year Ended		Year ended
	30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31.03.2025
ALGERIA		3.02	6.81	3.02	6.81	6.81
BANGLADESH		3.18		3.18	15.21	15.2
BARZIL				-		12.51
BOLIVIA				-	3.14	3.14
COLOMBIA	189.41	339.86	124.82	529.26	348.74	492.7
CZECH REPUBLIC		2.29	2.24	2.29	2.24	4.57
CHINA				-		0
EGYPT		184.92	187.45	184.92	351.09	520.06
ELSALVADOR	14.60	64.66	8.46	79.26	137.16	251.55
GERMANY			6.21	-	6.21	28.28
GUATEMALA CITY		26.72	18.49	26.72	27.08	96.82
IRAN				-		0
MEXICO	9.98	127.21	30.07	137.18	30.07	285.07
PERU		96.01	131.18	96.01	203.08	278.94
RUSSIA	5.00	5.00		10.00		0
SAUDI ARABIA				-		0
SPAIN				-		41.26
SWITZERLAND				-		0
TURKEY		1.04	1.41	1.04	1.41	1.62
THAILAND	12.17	24.99		37.15		24.95
UAE	2.79	36.30	72.06	39.09	89.41	86.51
VIETNAM	413.39	287.29	95.06	700.68	412.54	1092.51
<b>INDIA</b>	<b>2,280.71</b>	<b>1,366.12</b>	<b>1,784.34</b>	<b>3,646.83</b>	<b>2,967.80</b>	<b>6215.29</b>
	<b>2,928.04</b>	<b>2,568.59</b>	<b>2,468.59</b>	<b>5,496.63</b>	<b>4,602.00</b>	<b>9,457.79</b>

For Gennex Laboratories Limited

ARIHANT  
BAID  
ARIHANT BAID  
Managing Director  
DIN #01171845

Digitally signed  
by ARIHANT BAID  
Date: 2025.11.14  
17:12:52 +05'30'

Date: 14-11-2025

Place: Hyderabad